Prevalence of and Factors Influencing Impaired Glucose Tolerance Among Hepatitis B Carriers
A Nationwide Cross-Sectional Study in the Republic of Korea

Boyoung Park, MD, PhD, Kyu-Won Jung, MS, Chang-Mo Oh, MD, PhD, Kui Son Choi, PhD, Mina Suh, MD, PhD, and Jae Kwan Jun, MD, PhD

Abstract: Diabetes is associated with a poor prognosis for liver disease, particularly in chronic hepatitis carriers. We investigated the prevalence of factors associated with impaired glucose tolerance (IGT) including diabetes and impaired fasting glucose (IFG) among individuals with hepatitis B virus (HBV) infection.

We used data from the Korean National Health and Nutrition Examination Survey, a nationwide cross-sectional survey conducted between 2007 and 2011. Sociodemographic information was collected using a structured questionnaire. The HBV surface antigen, liver enzymes, and lipid profile were measured from blood samples.

IFG was found in 18.1% of HBV carriers and 19.3% of noncarriers (P = 0.25). Diabetes was observed in 10.0% of HBV carriers and 12.2% of noncarriers (P = 0.08). Lower level of educational attainment was associated with a higher prevalence of IGT: high school education (odds ratio [OR] = 1.94 [95% confidence interval (CI) 1.14–3.29]) and less than a high school education (OR = 3.20 [95% CI, 1.66–6.15]) vs more than or equal to a college education. Elevated alanine transaminase and triglyceride by 10 were associated with increased risk of IGT (OR = 1.10 [95% CI, 1.01–1.20] and OR = 1.04 [95% CI, 1.01–1.07], respectively). Being a man and older in age were associated with a higher prevalence of IGT, and individuals with a low body mass index were at lower risk for IGT.

Given the synergistic effect of diabetes and HBV infection on liver disease prognosis, we recommend targeted IGT screening and follow-up for HBV carriers. These efforts should include health policies and intervention programs aimed at reducing educational disparities and encouraging early control of elevated liver enzymes or lipid profiles.

(=91)

Abbreviations: ALT = alanine transaminase, AST = aspartate aminotransferase, BMI = body mass index, CI = confidence interval, HbA1c = hemoglobin A1c, HBV = hepatitis B virus, HBsAg = hepatitis B surface antigen, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, IFG = impaired fasting glucose, KNHANES = Korean National Health and Nutrition Examination Survey, OR = odds ratio, TG = triglyceride.

INTRODUCTION

The liver has a unique role in controlling carbohydrate metabolism by maintaining glucose level within the normal range.1 The association between increased insulin resistance and chronic liver disease is well known and beside those associated with lifestyle, which are known to increase the risk of type 2 diabetes, it may contribute to the pathophysiology of glucose intolerance in patients with liver diseases distintively.2 In most patients, insulin resistance and glucose intolerance develop in the early stages of chronic liver disease,3 and the natural history of diabetes caused by liver disease differs from that of type 2 diabetes.4 Diabetes or insulin resistance in patients with liver disease is associated with a poor prognosis including rapid progression, drug resistance, and poor control of glucose levels.4,5 Previous investigations of the relationship between cirrhosis of the liver and the development of impaired glucose tolerance have shown that 60% to 80% of patients with cirrhosis suffer from glucose intolerance and 20% to 60% of those have diabetes.6 Several previous studies have investigated whether viral infections of liver promote insulin resistance and cause impaired glucose metabolism, and most have focused on the hepatitis C viruses (HCVs) and hepatitis B viruses (HBVs) because of their chronicity.7 Although the association between HCV infection and the development of impaired glucose tolerance because of insulin resistance is widely acknowledged,8,9 the relationship between impaired glucose tolerance and HBV infection is controversial.8,9

Diabetes itself is a well-known independent risk factor for liver cirrhosis and hepatocellular carcinoma (HCC)10,11 and aggravates the condition.5 Diabetes increases the risk of liver cirrhosis11 and HCC12 in patients with an HBV or HCV infection, and recent reports have suggested that diabetes and hepatitis infection have a synergistic effect on the risk of developing HCC.13,14 Thus, patients with both HBV or HCV infection and impaired glucose tolerance are at high risk for advanced liver diseases such as cirrhosis and HCC.

HBV and HCV infections are major global public health issues with >2 billion HBV-infected individuals, 378 million chronic HBV carriers, and 130 million HCV-infected people worldwide.15,16 However, the regional distribution of HBV and HCV infection varies. HCV is more prevalent in
Western countries, whereas HBV is endemic to the Asia-Pacific region where 75% of chronic HBV carriers reside and 15% to 25% die of HBV-related liver diseases. The Republic of Korea had a high prevalence of HBV infection in the 1980s, and although the prevalence decreased following implementation of the nationwide vaccination program in 1995, the Republic of Korea remains one of the highest HBV-endemic areas in the Asia-Pacific region.

Given the high prevalence of HBV infection in the Republic of Korea and its potential association with diabetes, it is important to determine whether the prevalence of diabetes is higher among people infected with HBV than among those who are HBV negative. Thus, we compared the prevalence of diabetes and impaired fasting glucose (IFG) and diabetes management in HBV carriers with those in noncarriers. Moreover, we used a nationally representative sample of the Republic of Korea population to identify possible predictors of impaired glucose tolerance including IFG and diabetes, the major factors that act synergistically with HBV to cause liver disease progression in HBV carriers.

**METHODS**

**Study Population**

We used data from the Korean National Health and Nutrition Examination Survey (KNHANES) conducted between 2007 and 2011. The KNHANES is a population-based cross-sectional survey of a nationally representative sample in the Republic of Korea. The KNHANES was conducted every 3 years between 1998 and 2005 and has been conducted yearly since 2007 using an independent rolling survey sampling model. Trained interviewers used a standardized questionnaire to assess health-related behaviors, the medical examination was conducted by well-trained nurses and physicians, and a food-frequency questionnaire was used to assess dietary intake. The official KNHANES website describes the study in detail (http://knhanes.cdc.go.kr/). The study protocol was approved by the institutional review board of the Korea Centers for Disease Control and Prevention (IRB no. 2011-02CON-06-C) and the institutional review board of the National Cancer Center (IRB no. NCCNCS-08-129), and all participants provided written informed consent.

Among the 53,232 individuals sampled between 2007 and 2011, 42,347 agreed to participate in the survey (total response rate, 79.6%). Participants who were 30 years of age or older were included in the study. Individuals whose serum hepatitis B surface antigen (HBsAg) was positive were defined as HBV carriers and those whose serum HBsAg was negative were defined as HBV noncarriers. The data of people whose serum glucose level was not measured or whose fasting time was <8 hours were excluded from the study. A final total of 23,355 noncarriers and 916 carriers were included in the analysis (Figure 1).

**Data Collection**

Serum HBsAg, aspartate aminotransferase (AST), and alanine transaminase (ALT) were measured using an independent rolling survey sampling model. Fasting plasma glucose levels, triglycerides (TGs), and total cholesterol were measured using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan). We defined impaired glucose tolerance as fasting glucose ≥100 mg/dL or a hemoglobin A1c (HbA1c) level ≥6.5%, which included the criteria for IFG (fasting plasma glucose, 100–125 mg/dL) and diabetes (fasting plasma glucose, ≥126 mg/dL or HbA1c ≥6.5%). The health interview questionnaire comprised demographic and socioeconomic characteristics of the participants including sex, age, area of residence, monthly household income, educational attainment, previous and current diseases, subjective health status, smoking, drinking, and stress level. HBV carriers who reported they had been diagnosed with HBV infection by a physician were classified as being aware of their HBV infection status. Household income was categorized according to interquartile range. Height and weight measured during the medical examination was used to calculate the body mass index (BMI) by dividing weight by height squared (kg/m²), which was divided into 3 groups: <18.5 kg/m², 18.5 to 24.9 kg/m², and ≥25 kg/m². Smoking status was classified as current smokers and noncurrent smokers. Alcohol consumption was classified as heavy drinking and nonheavy drinking based on the results of previous studies showing that low-to-moderate alcohol consumption prevented the development of diabetes. Heavy drinking was defined as consuming alcohol twice or more often.

**FIGURE 1.** Flowchart of the study population. HBV = hepatitis B virus, KNHANES = Korean National Health and Nutrition Examination Surveys.
per week and consuming at least 7 drinks (for men) and 5 drinks (for women) on any given occasion.

Statistical Analyses

Survey sample weights, calculated taking the sampling rate, response rate, and age/sex stratification into consideration, were used in all analyses. The prevalence of IFG and diabetes among HBV carriers and noncarriers was compared using the \( \chi^2 \) test. In addition, HBV carriers and noncarriers with diabetes were compared according to the prevalence of diabetes recognition, defined as participants who had been diagnosed with diabetes by a physician; diabetes treatment, defined as participants who were prescribed insulin or oral antidiabetic agents; and diabetes control, defined maintaining an HbA1c level <6.5%.

Baseline characteristics of HBV carriers are expressed as percent and 95% confidence intervals (CIs). AST, ALT, TG, and total cholesterol levels are expressed as means (95% CIs). A univariate logistic regression analysis was used to identify factors associated with impaired glucose tolerance and the results were reported as odds ratios (ORs) and 95% CIs. We conducted a multiple logistic regression analysis to assess the independent effect of the variables with a \( P \) value <0.20 in the univariate logistic regression to avoid overadjustment by including an excessive number of variables. Missing information was treated as dummy. All statistical analyses were conducted using SAS software version 9.1 (SAS, Inc, Cary, NC).

RESULTS

Figure 2 shows the prevalence of IFG and diabetes in HBV carriers and noncarriers. We found no significant between-group differences in IFG (HBV carriers, 18.1% vs noncarriers, 19.3%; \( P = 0.25 \)) or diabetes (HBV carriers, 10.0% vs noncarriers, 12.2%; \( P = 0.08 \)). Moreover, the prevalence of diabetes recognition, treatment, and control was not significantly different between the HBV carriers and noncarriers (\( P = 0.66, 0.54, \) and 0.43, respectively).

Table 1 shows the characteristics of HBV carriers in the Republic of Korea. A total of 52.2% were men and 47.8% were women, and 60.8% had a normal BMI defined as 18.5 to 24.9 kg/m\(^2\). Most HBV carriers (78.9%) were not aware of their infection status: nearly 50% rated their health status as moderate, 43.8% were smokers, and 11.5% were heavy drinkers. The mean AST, ALT, TG, and total cholesterol were 28.8 IU/L (95% CI, 27.2–30.3), 29.9 IU/L (95% CI, 27.2–32.6), 116.5 mg/dL (95% CI, 111.1–121.9), and 184.6 mg/dL (95% CI, 182.0–187.2), respectively.

Table 2 shows the factors associated with impaired glucose tolerance in HBV carriers. Being a man, older in age, lower household income, lower educational attainment, smoking, and increments in AST, ALT, and TG levels were significantly associated with a higher risk of impaired glucose tolerance (\( P < 0.05 \)), whereas lower BMI was significantly associated with lower risk of impaired glucose tolerance.

Of the variables tested in the univariate analysis, sex, age, household income, educational attainment, BMI, smoking, AST, ALT, and TG levels that reached \( P < 0.20 \) were included in the multivariate analysis (Table 3). Being a man was significantly associated with a higher prevalence of impaired glucose tolerance (OR = 2.18 [95% CI, 1.28–3.72]). Old age was associated with impaired glucose tolerance: 40 to 49 years, OR = 2.34 (95% CI, 1.25–4.41); 50 to 59 years, OR = 2.31 (95% CI, 1.14–4.67); and \( \geq 60 \), OR = 3.28 (95% CI, 1.61–6.71) vs <40 years of age. Lower educational attainment was related to a higher prevalence of impaired glucose tolerance: high school education, OR = 1.94 (95% CI, 1.14–3.29) and less than a high school education, OR = 2.30 (95% CI, 1.66–6.15) vs more than or equal to a college education. People with lower BMI had a lower risk for impaired glucose tolerance: BMI 18.5 to 24.9 kg/m\(^2\), OR = 0.42 (95% CI, 0.29–0.61) and BMI <18.5 kg/m\(^2\), OR = 0.25 (95% CI, 0.05–1.24) compared with overweight participants. Increments of 10 in ALT and TG level increased the risk of impaired glucose tolerance (ALT; OR = 1.10 [95% CI, 1.01–1.20]; and TG, OR = 1.04 [95% CI, 1.01–1.07], respectively).

DISCUSSION

We found that 18.1% of HBV carriers in the Republic of Korea had IFG and 10.0% had diabetes. Furthermore, the percentages of IFG and diabetes were similar in noncarriers. Our results support several previous studies showing that in the absence of cirrhosis, the prevalence of diabetes among HBV carriers was not significantly different from that among noncarriers.
TABLE 1. Weighted Prevalence of Baseline Characteristics for HBV Carriers

| Characteristic                      | N     | Prevalence, % | 95% CI          |
|-------------------------------------|-------|---------------|-----------------|
| **Fasting glucose level**           |       |               |                 |
| Normal (<100 mg/dL)                | 655   | 72.0          | (68.5–75.4)     |
| IFG (100–125 mg/dL)                | 171   | 18.1          | (15.3–20.9)     |
| Diabetes (≥126 mg/dL or HbA1c ≥ 6.5%) | 90    | 10.0          | (7.5–12.4)      |
| **Sex**                            |       |               |                 |
| Men                                 | 442   | 52.2          | (48.4–56.0)     |
| Women                               | 474   | 47.8          | (44.0–51.6)     |
| **Age, y**                          |       |               |                 |
| 30–39                               | 224   | 25.5          | (22.1–29.0)     |
| 40–49                               | 238   | 27.0          | (23.4–30.6)     |
| 50–59                               | 214   | 23.7          | (20.3–27.2)     |
| ≥60                                 | 240   | 23.7          | (20.5–27.0)     |
| **Area of residence**               |       |               |                 |
| Urban                               | 680   | 78.8          | (74.7–82.8)     |
| Rural                               | 236   | 21.2          | (17.2–25.3)     |
| **Household income**                |       |               |                 |
| Low                                 | 158   | 15.3          | (12.6–18.0)     |
| Mid-low                             | 232   | 26.1          | (22.6–29.6)     |
| Mid-high                            | 228   | 26.3          | (22.8–29.8)     |
| High                                | 278   | 30.3          | (26.8–33.8)     |
| Missing                             | 20    | 1.9           | (0.9–2.9)       |
| **Education**                       |       |               |                 |
| <High school                        | 358   | 35.6          | (31.7–39.4)     |
| High school                         | 290   | 31.9          | (28.2–35.7)     |
| ≥College                            | 258   | 30.4          | (26.4–34.5)     |
| Missing                             | 10    | 2.1           | (0.8–3.4)       |
| **BMI, kg/m²**                      |       |               |                 |
| <18.5                               | 24    | 2.9           | (1.6–4.2)       |
| 18.5–24.9                           | 565   | 60.8          | (57.1–64.4)     |
| ≥25.0                               | 324   | 35.9          | (32.3–39.4)     |
| Missing                             | 3     | 0.5           | (0.0–1.1)       |
| **Awareness of HBV infection**      |       |               |                 |
| Unaware                             | 723   | 78.9          | (75.6–82.1)     |
| Aware                               | 193   | 21.1          | (17.9–24.4)     |
| **Subjective health status**        |       |               |                 |
| Poor                                | 227   | 21.2          | (18.2–24.3)     |
| Moderate                            | 420   | 50.2          | (46.3–54.2)     |
| Good                                | 259   | 26.5          | (23.0–29.9)     |
| Missing                             | 10    | 2.1           | (0.8–3.4)       |
| **Stress level**                    |       |               |                 |
| High                                | 242   | 24.0          | (20.8–27.2)     |
| Low                                 | 666   | 74.3          | (71.1–77.5)     |
| Missing                             | 8     | 1.7           | (0.5–2.8)       |
| **Smoking status**                  |       |               |                 |
| Current smoker                      | 372   | 43.8          | (39.9–47.7)     |
| Noncurrent smoker                   | 535   | 54.5          | (50.6–58.3)     |
| Missing                             | 9     | 1.8           | (0.6–2.9)       |
| **Alcohol drinking**                |       |               |                 |
| Heavy drinker                       | 93    | 11.5          | (9.0–14.0)      |
| Nonheavy drinker                    | 812   | 86.5          | (83.9–89.1)     |
| Missing                             | 11    | 2.0           | (0.8–3.3)       |
| **AST**                             |       |               |                 |
| Mean, IU/L                          | 916   | 28.8          | (27.2–30.3)     |
| **ALT**                             |       |               |                 |
| Mean, IU/L                          | 916   | 29.9          | (27.2–32.6)     |
| **TGs**                             |       |               |                 |
| Mean, mg/dL                         | 916   | 116.5         | (111.1–121.9)   |
| Total cholesterol                   | 916   | 184.6         | (182.0–187.2)   |

**ALT** = alanine transaminase, **AST** = aspartate aminotransferase, **BMI** = body mass index, **CI** = confidence interval, **HbA1c** = hemoglobin A1c, **HBV** = hepatitis B virus, **IFG** = impaired fasting glucose, **TG** = triglyceride.
as a marker for the severity of liver injury. Moreover, increased serum lipids resulting from abnormal fat metabolism contributes to impaired glucose tolerance by causing hepatic TG accumulation. Several previous studies have shown that high levels of liver enzymes such as ALT, or dyslipidemia are related to IFG or diabetes in HBV/HCV carriers. Our results indicate that elevated ALT or TG levels even below the threshold of abnormality can increase the risk for impaired glucose tolerance. Thus, close monitoring of liver enzymes and lipid profile to enable early control of elevated ALT and TG levels may be crucial for the prevention of impaired glucose tolerance in HBV carriers.

| TABLE 2. Weighted Univariate Logistic Regression Analysis of Factors Associated With IFG and Diabetes in HBV Carriers |
|---------------------------------------------------------------|
| **IFG and DM** | **Normal** | **OR** | **95% CI** | **P Value** |
| **Sex** | | | | |
| Men | 147 (60.6) | 295 (49.0) | 1.60 | (1.13–2.26) | 0.01 |
| Women | 114 (39.4) | 360 (51.0) | 1 | | |
| **Age, y** | | | | |
| 30–39 | 26 (10.6) | 198 (31.4) | 1 | | |
| 40–49 | 62 (26.6) | 176 (27.2) | 2.89 | (1.60–5.22) | <0.001 |
| 50–59 | 71 (27.0) | 143 (22.5) | 3.55 | (1.96–6.41) | <0.001 |
| ≥60 | 102 (35.8) | 138 (19.0) | 5.57 | (3.17–9.80) | <0.001 |
| **Area of residence** | | | | |
| Urban | 195 (80.3) | 485 (78.1) | 1.14 | (0.77–1.70) | 0.51 |
| Rural | 66 (19.7) | 170 (21.9) | 1 | | |
| **Household income** | | | | |
| Low | 61 (23.9) | 97 (12.5) | 2.35 | (1.37–4.02) | 0.002 |
| Mid-low | 70 (28.5) | 162 (25.9) | 1.34 | (0.84–2.16) | 0.22 |
| Mid-high | 55 (21.0) | 173 (29.1) | 0.88 | (0.54–1.43) | 0.60 |
| High | 68 (26.6) | 210 (32.5) | 1 | | |
| **Education** | | | | |
| <High school | 141 (53.1) | 217 (29.8) | 3.52 | (2.25–5.50) | <0.001 |
| High school | 66 (28.6) | 224 (34.2) | 1.65 | (1.07–2.54) | 0.02 |
| ≥College | 52 (18.3) | 208 (36.0) | 1 | | |
| **BMI, kg/m²** | | | | |
| <18.5 | 2 (1.1) | 22 (3.6) | 0.17 | (0.04–0.77) | 0.02 |
| 18.5–24.9 | 126 (46.4) | 439 (66.8) | 0.39 | (0.28–0.55) | <0.001 |
| ≥25.0 | 132 (52.5) | 192 (29.6) | 1 | | |
| **Awareness of HBV infection** | | | | |
| Unaware | 213 (80.3) | 510 (78.3) | 1.13 | (0.74–1.72) | 0.59 |
| Aware | 48 (19.7) | 145 (21.7) | 1 | | |
| **Subjective health status** | | | | |
| Poor | 78 (26.5) | 149 (19.8) | 1.28 | (0.81–2.03) | 0.29 |
| Moderate | 111 (45.5) | 309 (45.3) | 0.81 | (0.54–1.22) | 0.32 |
| Good | 68 (28.0) | 191 (26.7) | 1 | | |
| **Stress level** | | | | |
| High | 66 (23.2) | 176 (24.9) | 0.91 | (0.62–1.35) | 0.64 |
| Low | 192 (76.8) | 474 (75.1) | 1 | | |
| **Smoking status** | | | | |
| Current smoker | 122 (52.0) | 250 (41.7) | 1.51 | (1.09–2.11) | 0.02 |
| Noncurrent smoker | 135 (48.0) | 400 (58.3) | 1 | | |
| **Alcohol drinking** | | | | |
| Heavy drinker | 32 (14.5) | 61 (10.7) | 1.41 | (0.84–2.38) | 0.26 |
| Nonheavy drinker | 225 (85.5) | 587 (89.3) | 1 | | |
| **AST** | | | | |
| 10% increments, mean (SE) | 32.1 (1.6) | 27.5 (0.9) | 1.10 | (1.02–1.18) | 0.02 |
| ALT | 37.0 (4.2) | 27.1 (1.1) | 1.07 | (1.01–1.13) | 0.01 |
| TGs | 136.4 (5.6) | 108.7 (3.2) | 1.05 | (1.02–1.08) | <0.001 |
| **Total cholesterol** | | | | |
| 10% increments, mean (SE) | 186.8 (2.2) | 183.7 (1.6) | 1.02 | (0.98–1.07) | 0.32 |

ALT = alanine transaminase, AST = aspartate aminotransferase, BMI = body mass index, CI = confidence interval, DM = diabetes, HBV = hepatitis B virus, IFG = impaired fasting glucose, OR = odds ratio, SE = standard error, TG = triglyceride.
Other factors that were significantly associated with impaired glucose tolerance in our study, including male sex, older age, and being overweight, are well-known risk factors for the development of diabetes in the general population and in viral hepatitis carriers.

Our study had several limitations. First, we measured only HBsAg and hepatitis B surface antibodies because total hepatitis B core antibodies were not included in the KNHANES protocol. Thus, we were only able to assess current HBV infections. Second, a previous study found a strong association between IFG and the hepatitis B e-antigen, a marker for HBV replication and infectivity, and an increase in γ-glutamyl transferase, which may reflect hepatic oxidative stress. We were unable to compare our results with theirs because data were lacking in our study. Third, our cross-sectional study design did not allow us to assess the causal order of the association (temporal relationship) among HBV infection, sociodemographic, and laboratory factors and the development of impaired glucose tolerance.

Fourth, the information collected from the health interview was self-reported and may have been subject to information or recall bias. However, a major strength of our study is that the data were obtained from a nationally representative survey, and we applied sampling weights in the analysis to represent the entire Korean population. Thus, the results are representative and may be generalized to all HBV carriers in Asian countries whose HBV epidemiology is similar to that of Korea. Moreover, to the best of our knowledge, the present study is the first to investigate the prevalence of impaired glucose tolerance, diabetes management, and associated sociodemographic factors in HBV carriers.

The burden of liver disease related to HBV infection is substantial. In the Republic of Korea, mortality related to liver cancer and liver disease is considerable; liver cancer is the fifth most commonly diagnosed cancer and the second leading cause of cancer-related death. Given that diabetes is associated with a poor prognosis for liver disease and the development of liver cirrhosis and HCC in HBV carriers, it is imperative that factors associated with the development of diabetes are well managed in people with an HBV infection to prevent the development of end-stage liver disease. Both IFG (plasma glucose, 100–125 mg/dL) and diabetes (plasma glucose, ≥126 mg/dL or HbA1c ≥6.5%) should be monitored in HBV carriers because the natural history of diabetes is a spectrum involving IFG in the early stage. We found that the following factors were associated with impaired glucose tolerance: being a man, older age, lower educational attainment, higher BMI, and increasing increments of ALT and TG levels. Of these factors, it is most important to focus on those that can be modified to decrease the risk of impaired glucose tolerance, such as education and weight control, because of their high impact and association with high mortality resulting from liver disease. HBV carriers with impaired glucose tolerance are at high risk for end-stage liver disease, and therefore HBV carriers should be considered for surveillance programs that closely monitor liver enzymes and lipid profile and detect changes in ALT and TG levels, so that elevations can be rapidly controlled to prevent impaired glucose tolerance in HBV carriers at an early stage.

### References

1. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. *Diabetes Metab*. 2004;30:398–408.

2. Kawaguchi T, Taniguchi E, Itou M, et al. Insulin resistance and chronic liver disease. *World J Hepatol*. 2011;3:99–107.

3. Buzzelli G, Chiarantini E, Cotrozzi G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. *Liver*. 1988;8:354–359.

4. Garcia-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. *Ann Hepatol*. 2009;8:13–20.

5. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. *World J Gastroenterol*. 2009;15:280–288.

6. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Mendez-Sanchez N. Viral hepatitis infection and insulin resistance: a review of the pathophysiological mechanisms. *Salud Publica Mex*. 2011; 53(suppl 1):S46–S51.

### Table 3. Weighted Multivariate Logistic Regression Analysis of Factors Associated With IFG and Diabetes in HBV Carriers

| Factor                        | OR     | 95% CI  |
|-------------------------------|--------|---------|
| Sex                           |        |         |
| Men                           | 2.18   | (1.28–3.72)* |
| Women                         | 1      |         |
| Age, y                        |        |         |
| <40                           | 1      |         |
| 40–49                         | 2.34   | (1.25–4.41)* |
| 50–59                         | 2.31   | (1.14–4.67)** |
| ≥60                           | 3.28   | (1.61–6.71)* |
| Household income              |        |         |
| Low                           | 1.26   | (0.66–2.40) |
| Mid-low                       | 0.87   | (0.51–1.51) |
| Mid-high                      | 0.90   | (0.52–1.55) |
| High                          | 1      |         |
| Education                     |        |         |
| <High school                  | 3.20   | (1.66–6.15)* |
| High school                   | 1.94   | (1.14–3.29)** |
| ≥College                      | 1      |         |
| BMI, kg/m²                    |        |         |
| <18.5                         | 0.25   | (0.05–1.24) |
| 18.5–24.9                     | 0.42   | (0.29–0.61)** |
| ≥25.0                         | 1      |         |
| Smoking status                |        |         |
| Current smoker                | 0.93   | (0.56–1.55) |
| Noncurrent smoker             | 1      |         |
| AST                           |        |         |
| 10 increments                 | 0.97   | (0.86–1.09) |
| ALT                           |        |         |
| 10 increments                 | 1.10   | (1.01–1.20)** |
| TGs                           |        |         |
| 10 increments                 | 1.04   | (1.01–1.07)** |

ALT = alanine transaminase, AST = aspartate aminotransferase, BMI = body mass index, CI = confidence interval, HBV = hepatitis B virus, IFG = impaired fasting glucose, OR = odds ratio, TG = triglyceride.

*P < 0.01.

**P < 0.05.

†P values < 0.20 in the univariate analysis were included.
7. Naing C, Mak JW, Ahmed SI, et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18:1642–1651.

8. Mavrogianaki A, Karamanos B, Manesis EK, et al. Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case–control study. J Viral Hepat. 2009;16:430–436.

9. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–468.

10. Zheng Z, Zhang C, Yan J, et al. Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case–control study in hepatitis endemic area. PloS one. 2013;8:e84776.

11. Tao T, Wu JC, Lee PC, et al. Diabetes mellitus as a risk factor of liver cirrhosis in patients with chronic hepatitis B virus infection. J Clin Gastroenterol. 2000;30:250–254.

12. Polesel J, Zucchetto A, Montella M, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2009;20:355–367.

13. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–121.

14. Yuan JM, Govindarajan S, Arakawa K, et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer. 2004;101:1099–1107.

15. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13:2436–2441.

16. WHO. Weekly epidemiological record. World Health Organization. 2009;84:405–420. http://www.who.int/wer/2009/wer8440.pdf.

17. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges. J Hepatol. 2009;51:403–410.

18. Chan HL, Jia J. Chronic hepatitis B in Asia—new insights from the past decade. J Gastroenterol Hepatol. 2011;26(suppl 1):131–137.

19. Chae HB, Kim JH, Kim JK, et al. Current status of liver diseases in Korea: hepatitis B. Korean J Hepatol. 2009;15(suppl 6):S13–S24.

20. Cullmann M, Hilding A, Ostenson CG. Alcohol consumption and risk of pre-diabetes and type 2 diabetes development in a Swedish population. Diab Med. 2012;29:441–452.

21. Rasouli B, Ahlborn A, Andersson T, et al. Alcohol consumption is associated with reduced risk of type 2 diabetes and autoimmunity of diabetes in adults: results from the Nord-Trondelag health study. Diabet Med. 2013;30:56–64.

22. Kumar M, Choudhury A, Manglik N, et al. Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol. 2009;104:76–82.

23. Huang ZS, Huang YS, Wu TH, et al. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. J Gastroenterol Hepatol. 2010;25:1420–1425.

24. Li-Ng M, Tropp S, Danoff A, et al. Association between chronic hepatitis B virus infection and diabetes among Asian Americans and Pacific Islanders. Dig Liver Dis. 2007;39:549–556.

25. Gundling F, Seidl H, Strassen I, et al. Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion. 2013;87:75–84.

26. Borrell LN, Dallo FJ, White K. Education and diabetes in a racially and ethnically diverse population. Am J Public Health. 2006;96:1637–1642.

27. Icks A, Moebus S, Feuersenger A, et al. Diabetes prevalence and association with social status—widening of a social gradient? German national health surveys 1990–1992 and 1998. Diabetes Res Clin Pract. 2007;78:293–297.

28. Khang YH, Lynch JW, Kaplan GA. Health inequalities in Korea: age- and sex-specific educational differentials in the 10 leading causes of death. Int J Epidemiol. 2004;33:299–308.

29. Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins [Epub ahead of print]. Clin Exp Med. 2013. doi:10.1007/s10238-013-0262-5.

30. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987–1000.

31. Iroeziindu MO, Isiguzo GC, Young EE. Prevalence and predictors of impaired fasting glucose among Nigerian patients with hepatitis B virus infection. Diabetes Res Clin Pract. 2012;98:338–345.

32. Mainous AG 3rd, Diaz VA, King DE, et al. The relationship of hepatitis antibodies and elevated liver enzymes with impaired fasting glucose and undiagnosed diabetes. J Am Board Fam Med. 2008;21:497–503.

33. Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006;13:303–310.

34. Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006;1084:1–29.

35. Qiao Q, Hu G, Tuomilehto J, et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003;26:1770–1780.

36. Arai M, Murase K, Kusakabe A, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol. 2003;38:355–360.

37. Ryu JK, Lee SB, Hong SJ, et al. Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients. Korean J Intern Med. 2001;16:18–23.

38. Jung KW, Won YJ, Hong JK, et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Jpn J Cancer Res. 2013;104:1–14.